Dose Carcinogenicity of Potassium Bromate, KBrO3 in the Rat Kidney

LOW-DOSE CARCINOGENICITY OF POTASSIUM BROMATE, KBRO3 IN THE RAT KIDNEY  

Einally, the renal carcinogenicity of potassium bromate was examined using a two-stage carcinogenesis model. A total of 240 male Wistar rats were treated with iV-ethyl-A-hydroxyethylnitrosamine for the initiahon of kidney carcinogenesis and were thereafter administered potassium bromate at doses of 0, 0.02, 0.2, 2, 8, 30, 125, and 500ppm in their drinking water for 16 weeks (Wei et al. 2009) Due to 

8-OHdG formation levels (A) and LacI gene mutation frequencies (B, C) in of Big Blue rats treated with KB1O3 for 16 weeks. ( ) p 0.05 versus Oppm 

The results of these two sets of experiments support the conclusion that there is a no-effect level and threshold dose for potassium bromate renal carcinogenicity in the rat. 

Wanibuchi, H., Salim, E. I., Morimura, K., Kinoshita, A., Kudoh, S., Hirata, K., Yoshikawa, J., and Fukushima, S. (2005). Lack of large intestinal carcinogenicity of 2-amino-l-methyl-6-phenylimidazo[4,5-i)]pyridine at low doses in rats initiated with azoxymethane. Int J Cancer 115, 870-878. 

---